TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States.
The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody.
TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 16.9K |
| Three Month Average Volume | 2.5M |
| High Low | |
| Fifty-Two Week High | 14.746 USD |
| Fifty-Two Week Low | 0.002 USD |
| Fifty-Two Week High Date | 13 Mar 2024 |
| Fifty-Two Week Low Date | 31 Jul 2024 |
| Price and Volume | |
| Current Price | 0.09 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -46.76% |
| Thirteen Week Relative Price Change | -93.43% |
| Twenty-Six Week Relative Price Change | -97.82% |
| Fifty-Two Week Relative Price Change | -98.64% |
| Year-to-Date Relative Price Change | -97.83% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -92.97% |
| Twenty-Six Week Price Change | -97.61% |
| Five Day Price Change | -27.86% |
| Fifty-Two Week Price Change | -98.30% |
| Year-to-Date Price Change | -97.43% |
| Month-to-Date Price Change | 0.11% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.36548 USD |
| Book Value Per Share (Most Recent Quarter) | -0.90651 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.36548 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.90651 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.03072 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 7.35667 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.38826 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.19143 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 3.79272 USD |
| Normalized (Last Fiscal Year) | -0.74086 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.19143 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 3.80638 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.19143 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 3.79272 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.86899 USD |
| Cash Per Share (Most Recent Quarter) | 1.84003 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.18288 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 2.25982 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 3.99905 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -693 |
| Cash Flow Revenue (Trailing Twelve Months) | 288 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 162.34% |
| Pretax Margin (Last Fiscal Year) | -29.79% |
| Pretax Margin (5 Year) | -813.81% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -76.99% |
| Operating Margin (Trailing Twelve Months) | -228.28% |
| Operating Margin (5 Year) | -839.59% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -29.79% |
| Net Profit Margin (Trailing Twelve Months) | 162.34% |
| Net Profit Margin (5 Year) | -813.81% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99.39% |
| Revenue Growth (3 Year) | 32.05% |
| Revenue Change (Trailing Twelve Months) | -64.44% |
| Revenue Per Share Growth | -19.87% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 76.90% |
| EPS Change (Trailing Twelve Months) | 116.12% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 0 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 0 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -6,270,000 |
| Net Debt (Last Fiscal Year) | -8,564,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 0 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 13 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 0 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 0 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -1 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 3.7M |
| Free Cash Flow (Trailing Twelve Months) | 9.2M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -1 |
| Net Interest Coverage (Trailing Twelve Months) | -19 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -24.26% |
| Return on Assets (Trailing Twelve Months) | 53.04% |
| Return on Assets (5 Year) | -79.42% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -236.44% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -177.85% |